Cargando…
510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study
Autores principales: | Thornton, C., Kalikin, L., Sanders, D., McClellan, S., LeBar, W., VanDevanter, D., Heltshe, S., Caverly, L., LiPuma, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Cystic Fibrosis Society.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527872/ http://dx.doi.org/10.1016/S1569-1993(22)01200-0 |
Ejemplares similares
-
157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
por: VanDevanter, D., et al.
Publicado: (2021) -
Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis
por: Carmody, Lisa A., et al.
Publicado: (2018) -
The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation
por: Carmody, Lisa A, et al.
Publicado: (2015) -
Culture-Independent Identification of Nontuberculous Mycobacteria in Cystic Fibrosis Respiratory Samples
por: Caverly, Lindsay J., et al.
Publicado: (2016) -
Parallel Analysis of Cystic Fibrosis Sputum and Saliva Reveals Overlapping Communities and an Opportunity for Sample Decontamination
por: Lu, Junnan, et al.
Publicado: (2020)